TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31314614

Group type: EXPERIMENTAL
Intervention: Intervention not specified; details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified; details not available
Number of subjects: 0
Study: 31314668

Group type: EXPERIMENTAL
Intervention: Subcallosal cingulate cortex deep brain stimulation (SCC-DBS)
Number of subjects: 0
Study: 31314757

Group type: EXPERIMENTAL
Intervention: Ivermectin-naive PWE in Logo health zone
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Onchocerciasis-infected PWE in Aketi health zone
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Skin snip-positive PWE
Number of subjects: 501
Study: 31314907

Group type: EXPERIMENTAL
Intervention: Targeted interventions
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 51
Study: 31315600

Group type: EXPERIMENTAL
Intervention: Early Check program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current models of newborn screening
Number of subjects: 0
Study: 31315608

Group type: EXPERIMENTAL
Intervention: Comprehensive dataset of biomarkers measured longitudinally
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Clinical assessment including motor and neuro-psychological tests
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Collection of biospecimens (stool, whole blood, cerebrospinal fluid)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (structural and functional)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: ECG recordings (12-lead and Holter)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Physiological and environmental data collection via Verily Study Watch
Number of subjects: 650
Study: 31315794

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 336
Study: 31315858

Group type: EXPERIMENTAL
Intervention: Play.Care algorithm using data from iPad games
Number of subjects: 760
Study: 31315863

Group type: EXPERIMENTAL
Intervention: Ethiopian Healthy Eating Index (EHEI) based on Food-Based Dietary Guidelines (FBDGs) using National Food Consumption Survey (NFCS) data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EHEI Score based on 24 hours diet recall.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food Quality Screening tool scoring for important EHEI components.
Number of subjects: 0
Study: 31315881

Group type: EXPERIMENTAL
Intervention: HSCP team intervention in the ED
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31315916

Group type: EXPERIMENTAL
Intervention: Youth with Down syndrome (DS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Typically developing youth (control)
Number of subjects: 100
Study: 31316378

Group type: EXPERIMENTAL
Intervention: Four off-label metabolically targeted medicines
Number of subjects: 0
Study: 31316451

Group type: EXPERIMENTAL
Intervention: Home-Based High-Intensity Interval Training
Number of subjects: 0
Study: 31316452

Group type: EXPERIMENTAL
Intervention: Retrospective pre-injury symptom ratings
Number of subjects: 0
Study: 31316785

Group type: EXPERIMENTAL
Intervention: Single-dose fecal microbiota transplant (FMT)
Number of subjects: 10
Study: 31316786

Group type: EXPERIMENTAL
Intervention: Treatment for diverticular disease
Number of subjects: 1206
Study: 31316836

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study: 31316984

Group type: EXPERIMENTAL
Intervention: Vibrating device (19 min plantar vibrating sequence)
Number of subjects: 29
Study: 31317047

Group type: EXPERIMENTAL
Intervention: Matrix-associated autologous chondrocyte implantation (ACI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 102
Study: 31317619

Group type: EXPERIMENTAL
Intervention: Opioid prescription at discharge
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Opioid use during the 2 weeks after ED visit
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Overall opioid use at 3-month follow-up
Number of subjects: 524
Study: 31318125

Group type: EXPERIMENTAL
Intervention: Surgery during pregnancy (23 patients, 59%)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Chemotherapy (20 patients, 51%)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Live births (31 live births reported)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Breastfeeding (3 patients)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comprehensive staging (13 patients)
Number of subjects: 39
Study: 31318273

Group type: EXPERIMENTAL
Intervention: ECE staff comfort level in discussing healthy sleep with parents
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Incorporation of sleep education into ECE
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stakeholder relevance rating of healthy sleep
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stakeholder priority rating of healthy sleep
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Knowledge about links to health and development
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recommendations for linking sleep health to other issues
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Need for awareness campaign
Number of subjects: 46
Study: 31318840

Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) analysis of solithromycin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Liquid Plasma Samples (LPS) analysis of solithromycin
Number of subjects: 95
Study: 31318902

Group type: EXPERIMENTAL
Intervention: Low-calorie formula diet for six weeks followed by nine weeks of food reintroduction and stabilization
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-calorie formula diet for six weeks
Number of subjects: 12
Study: 31318954

Group type: EXPERIMENTAL
Intervention: Blood lead level quartile
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 204
Study: 31319038

Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: LPS + ATP stimulation
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: LPS + ATP + P2X7 selective inhibitor
Number of subjects: 171

Group type: COMPARATOR
Intervention: P2RX7 diplotypes
Number of subjects: 171
Study: 31319153

Group type: EXPERIMENTAL
Intervention: HLA-identical sibling donors (MSDs)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Matched donors (MDs)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell graft recipients
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Grade I-II aGVHD
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Grade III-IV aGVHD
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Extensive cGVHD
Number of subjects: 348
Study: 31319498

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31319809

Group type: EXPERIMENTAL
Intervention: Functional autonomy level change as assessed by the instrumental abilities of daily living (IADL) score
Number of subjects: 6780

Group type: EXPERIMENTAL
Intervention: Cognitive performance and behavioral disorders changes over time
Number of subjects: 6780
Study: 31319833

Group type: EXPERIMENTAL
Intervention: f-IPF
Number of subjects: 79
Study: 31319851

Group type: EXPERIMENTAL
Intervention: Pre-dose PEF measured at home
Number of subjects: 8

Group type: COMPARATOR
Intervention: Forced expiratory volume in one second (FEV)
Number of subjects: 8
Study: 31319977

Group type: EXPERIMENTAL
Intervention: Carboplatin and nab-paclitaxel
Number of subjects: 63
Study: 31319994

Group type: EXPERIMENTAL
Intervention: Afatinib (50 mg once daily) plus Ruxolitinib (25 mg twice daily)
Number of subjects: 30
Study: 31320006

Group type: EXPERIMENTAL
Intervention: vHPSD catheter ablation
Number of subjects: 52
Study: 31320010

Group type: EXPERIMENTAL
Intervention: Stochastic trajectory analysis of ranked signals (STAR) mapping method
Number of subjects: 35
Study: 31320346

Group type: EXPERIMENTAL
Intervention: Integrated regional STEMI care networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPCI hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPCI hospital-based regional STEMI care network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-city STEMI care network
Number of subjects: 0
Study: 31320352

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 21 days for 6 weeks after the final dose of BCG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and intravesicular BCG therapy
Number of subjects: 15
Study: 31320356

Group type: EXPERIMENTAL
Intervention: EEG/ERP data recorded for 24 consecutive hours at five time points over 30 days.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (20 participants) with 15-hour EEG/ERP recording for baseline comparison.
Number of subjects: 50
Study: 31320358

Group type: EXPERIMENTAL
Intervention: Home-based screening using dried blood spot (DBS) sampling and collection of sociodemographic, economic and behavioural data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based screening and first clinic visit.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparisons of health and economic outcomes between households affected by HBV versus non-affected households.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic evaluation of scaling-up HBV care.
Number of subjects: 0
Study: 31320445

Group type: EXPERIMENTAL
Intervention: Regression to normal glucose regulation (NGR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average A1C during follow-up
Number of subjects: 0
Study: 31320894

Group type: EXPERIMENTAL
Intervention: Electromagnetic Shock Wave Therapy
Number of subjects: 0
Study: 31321070

Group type: EXPERIMENTAL
Intervention: Adapted resistance training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31321442

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4036

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 4036
Study: 31321485

Group type: EXPERIMENTAL
Intervention: TNFi monotherapy (existing use)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: csDMARD monotherapy (existing use)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Combination therapy (existing use)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: TNFi monotherapy (initiated use)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: csDMARD monotherapy (initiated use)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Combination therapy (initiated use)
Number of subjects: 700
Study: 31321631

Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg + single-dose rosuvastatin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg + single-dose atorvastatin 10 mg
Number of subjects: 0
Study: 31321875

Group type: EXPERIMENTAL
Intervention: DTG + RPV
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: DTG + darunavir/COBI
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: DTG
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: COBI
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (no transporter inhibitor)
Number of subjects: 288
Study: 31322059

Group type: EXPERIMENTAL
Intervention: Baseline placental growth factor concentrations in incident T2DM cases
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Reference subcohort
Number of subjects: 1052
Study: 31322652

Group type: EXPERIMENTAL
Intervention: Obese individuals with higher cardiorespiratory fitness
Number of subjects: 138

Group type: COMPARATOR
Intervention: Normal weight individuals
Number of subjects: 138
Study: 31322672

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 70

Group type: COMPARATOR
Intervention: RYGB only (Control)
Number of subjects: 70
Study: 31322702

Group type: EXPERIMENTAL
Intervention: BYL719 (phosphatidylinositol-3-kinase α inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (mammalian target of rapamycin inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of BYL719 and Everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BYL719 alone or in combination with Everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BYL719 plus Everolimus in human pheochromocytoma primary cultures
Number of subjects: 0
Study: 31323045

Group type: EXPERIMENTAL
Intervention: Duloxetine (active medication)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 41
Study: 31323075

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Raltegravir (RAL)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Darunavir/Ritonavir (DRV/r)
Number of subjects: 3
Study: 31323705

Group type: EXPERIMENTAL
Intervention: REP 2139-Ca therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated matched controls
Number of subjects: 12
Study: 31324189

Group type: EXPERIMENTAL
Intervention: rs2076295 in the DSP gene
Number of subjects: 4685

Group type: EXPERIMENTAL
Intervention: Lung function based polygenic risk score
Number of subjects: 4685
Study: 31324256

Group type: EXPERIMENTAL
Intervention: ReWalk exoskeleton training
Number of subjects: 11
Study: 31324600

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg intravenous infusions over six 4-weekly cycles and ibrutinib 420 mg oral once per day for 9 months
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg oral once per day for 6 additional months (for patients with complete response and minimal residual disease <0.01%)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg oral once per day plus fludarabine, cyclophosphamide, and obinutuzumab 1000 mg for 6 months (for patients with partial response or complete response with minimal residual disease ≥0.01%)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Adverse events during treatment
Number of subjects: 135
Study: 31324679

Group type: EXPERIMENTAL
Intervention: Frailty (defined by GFI ≥4)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Prefracture health status (HS)
Number of subjects: 696
Study: 31325010

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 0
Study: 31325020

Group type: EXPERIMENTAL
Intervention: Positional therapy (PT)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 292
Study: 31325044

Group type: EXPERIMENTAL
Intervention: hsTnT undetectable (<5 ng/L)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: hsTnT normal (5-14 ng/L)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: hsTnT stable elevated (15-51 ng/L)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: hsTnT >99th percentile
Number of subjects: 280

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Coronary angiography (CA)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Significant obstructive coronary artery disease requiring PCI
Number of subjects: 280
Study: 31325105

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 27
Study: 31326088

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Drug-independent system
Number of subjects: 102
Study: 31326397

Group type: COMPARATOR
Intervention: CDK4
Number of subjects: 260

Group type: COMPARATOR
Intervention: CDKN2A
Number of subjects: 260
Study: 31326957

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco (WPT) smoking session with 10 g of WPT and 470 mL of water
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Waterpipe device cleaning practices
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Disposal practices for smoked WPT residue
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Disposal practices for postsmoking charcoal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Disposal practices for smoked WP water
Number of subjects: 50
Study: 31327453

Group type: EXPERIMENTAL
Intervention: Watchful Waiting
Number of subjects: 0
Study: 31327618

Group type: EXPERIMENTAL
Intervention: MBEVAR for TAAAs and PRAAs in patients with prior aortic dissections
Number of subjects: 162

Group type: COMPARATOR
Intervention: MBEVAR for TAAAs and PRAAs in patients without prior aortic dissections
Number of subjects: 162
Study: 31328895

Group type: EXPERIMENTAL
Intervention: Alternate-Day Fasting (ADF)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Daily Calorie Restriction (CR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 43
Study: 31329313

Group type: EXPERIMENTAL
Intervention: Omalizumab + peanut oral immunotherapy (pOIT)
Number of subjects: 23
Study: 31329510

Group type: EXPERIMENTAL
Intervention: MoistureMeterD Compact Device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitting Test
Number of subjects: 0
Study: 31329854

Group type: EXPERIMENTAL
Intervention: Manual global long-axis strain (LAS) assessment
Number of subjects: 1235
Study: 31329922

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 3.6 mg administered at least 24 h after cabazitaxel infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m2 every 3 weeks, up to 10 cycles, with oral prednisolone 10 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study: 31330239

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Disruptive Mood Dysregulation Disorder (DMDD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Healthy Volunteers (HV)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD) and Disruptive Mood Dysregulation Disorder (DMDD)
Number of subjects: 118
Study: 31330556

Group type: EXPERIMENTAL
Intervention: 25 G fine-needle aspiration (FNA) followed by 20 G fine-needle biopsy (FNB)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 20 G fine-needle biopsy (FNB) followed by 25 G fine-needle aspiration (FNA)
Number of subjects: 73
Study: 31331295

Group type: EXPERIMENTAL
Intervention: Olaratumab (60 mg/kg twice weekly) + mouse anti-PDGFRA antibody 1E10 (20 mg/kg twice weekly)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Doxorubicin (3 mg/kg once weekly)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and anti-PDGFRA
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study: 31331342

Group type: EXPERIMENTAL
Intervention: TNF blockade
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-TNF blockade
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study: 31331370

Group type: EXPERIMENTAL
Intervention: Adjuvant Folfox Cetuximab after complete cytoreductive surgery (CCS)
Number of subjects: 12
Study: 31331393

Group type: EXPERIMENTAL
Intervention: Educational and nutritional interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duodenal biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RNA-Seq
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omic analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioinformatic tools
Number of subjects: 0
Study: 31331399

Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 128
Study: 31331591

Group type: EXPERIMENTAL
Intervention: Truncal regional anaesthesia (TRA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 122
Study: 31331701

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg/day) continuously until disease progression or unacceptable toxicity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg/day)
Number of subjects: 26
Study: 31331917

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily, lenalidomide, and rituximab
Number of subjects: 0
Study: 31331918

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for patients achieving complete response (CR) on PET scan after cycle 2 (PET2)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: eBEACOPP (escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for patients not achieving CR on PET2
Number of subjects: 331

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 331

Group type: COMPARATOR
Intervention: eBEACOPP
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 331
Study: 31331994

Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 46
Study: 31332032

Group type: EXPERIMENTAL
Intervention: Insulin Dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31332046

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 7
Study: 31332062

Group type: EXPERIMENTAL
Intervention: Nevirapine pharmacokinetics (PK) evaluated during anti-TB therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nevirapine pharmacokinetics (PK) evaluated after completing anti-TB therapy
Number of subjects: 53
Study: 31332068

Group type: EXPERIMENTAL
Intervention: WCK 4282 (Cefepime-Tazobactam Combination)
Number of subjects: 48
Study: 31332649

Group type: EXPERIMENTAL
Intervention: Single-dose 12/400-µg Formoterol/Budesonide combination
Number of subjects: 33
Study: 31333075

Group type: EXPERIMENTAL
Intervention: Primary cardiomyopathy patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Genetic variants of interest
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement
Number of subjects: 60
Study: 31333456

Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine combined with EGFR-TKI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31333489

Group type: COMPARATOR
Intervention: Healthy Sedentary (HS)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Healthy Active (HA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sedentary Patients with Increased CV Risk (SR)
Number of subjects: 140
Study: 31333511

Group type: EXPERIMENTAL
Intervention: Dextromethorphan as an add-on therapy to Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 0
Study: 31334125

Group type: EXPERIMENTAL
Intervention: Topical Diclofenac
Number of subjects: 0